Antifungal and antiviral agents: A review

Cancer Investigation

Volumn 17, Issue 2, 1999, Pages 145-152

  Shuter, Jonathan ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Montefiore Rikers Island Hlth Svc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMANTADINE; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; CIDOFOVIR; FAMCICLOVIR; FLUCONAZOLE; FLUCYTOSINE; FOSCARNET SODIUM; ITRACONAZOLE; KETOCONAZOLE; NYSTATIN; RIBAVIRIN; RIMANTADINE; VALACICLOVIR; VIDARABINE;

ANTIFUNGAL ACTIVITY; ANTIVIRAL ACTIVITY; BONE MARROW SUPPRESSION; CHILL; DRUG ABSORPTION; DRUG ELIMINATION; DRUG HALF LIFE; FEVER; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERSENSITIVITY; MYCOSIS; NAUSEA; PRIORITY JOURNAL; REVIEW; VIREMIA; VOMITING;

EID: 0033006799     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1080/07357909909011729     Document Type: Review

References (31)

1. Terrell CL, Hughes MD: Antifungal agents used for deep-seated mycotic infections. Mayo Clin Proc 67:69-91, 1992.
2. Hoeprich PD: Clinical use of amphotericin B and derivatives: lore, mystique, and fact. Clin Infect Dis 14(Suppl 1):S114-S119, 1992.
3. Goodwin SD, Cleary JD, Walawander CA, et al: Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin Infect Dis 20:755-761, 1995.
4. Oldfield EC, Garst PD, Hostettler C, et al: Randomized double-blind trial of 1- versus 4- hour amphotericin B infusion durations. Antimicrob Agents Chemother 34:1402-146, 1990.
5. Fields BT, Bates JH, Abernathy RS: Effect of rapid intravenous infusion on serum concentrations of amphotericin B. Appl Microbiol 22:615-617, 1971.
6. Williams C, Whitehous JMA, Lister TA, et al: Oral anticandidal prophylaxis in patients undergoing chemotherapy for acute leukemia. Med Pediatr Oncol 3:275-280, 1977.
7. Rex JH, Bennett JE, Sugar AM, et al: A randomized trial comparing fiuconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 331:1325-1330, 1994.
8. Anaissie E, Bodey GP, Kantarjian H, et al: Fiuconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 91:142-150, 1991.
9. Bennett JE: Antifungal agents. In: Principles and Practice of Infectious Diseases, edited by GL Mandell, JE Bennett, and R Dolin, New York, Churchill Livingstone, 1995, pp 401-410.
10. Slavin MA, Osborne B, Adams R, et al: Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 171:1545-1552, 1995.
11. Winston DJ, Chandrasekar PH, Lazarus HM, et al: Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a double-blind, multicenter trial. Ann Intern Med 118:495-503, 1993.
12. Wingard JR, Merz WG, Rinaldi MR, et al: Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fiuconazole. N Engl J Med 325:1274-1277, 1991.
13. Denning DW, Lee JY, Hosteller JS, et al: NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 97:135-144, 1994.
14. Bennett JE, Dismukes WE, Duma RJ, et al: A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 301:126-131, 1979.
15. Francis P, Walsh TJ: Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis 15:1003-1018, 1992.
16. Sugar AM: Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrob Agents Chemother 39:1907-1912, 1995.
17. Wood MJ, Kay R, Dworkin RH, et al: Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 22:341-347, 1996.
18. Meyers JD, Reed EC, Shepp DH, et al: Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 318:70-75, 1988.
19. Tyring S, Barbarash RA, Nahlik JE, et al: Famciclovir for the treatment of acute herpes zoster: effects on acute disease and post-herpetic neuralgia. Ann Intern Med 123;89-96, 1995.
20. Beutner KR, Friedman DJ, Forszpaniak C, et al: Valacyclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 39:1546-1553, 1995.
21. Goodrich JM, Bowden RA, Fisher L, et al: Prevention of cytomegalovirus disease after allogeneic marrow transplant by ganciclovir prophylaxis. Ann Intern Med 118:173-178, 1993.
22. Zaia JA, Forman SJ: Cytomegalovirus infection in the bone marrow transplant recipient. Infect Dis Clin North Am 9:879-900, 1995.
23. Reusser P, Gambertoglio JG, Lilleby K, et al: Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. J Infect Dis 166:473-479, 1992.
24. Whitley RJ, Soong SJ, Hirsch MS, et al: Herpes simplex encephalitis: vidarabine therapy and diagnostic problems. N Engl J Med 304:313-318, 1981.
25. 1. JAMA 245:1128-1131, 1981.
26. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trial Group: Combination fos-carnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS: the Cytomegalovirus Retreatment Trial. Arch Ophthalmol 114:23-33, 1996.
27. Bacigalupo A, Bregante S, Tedone E, et al: Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation. Transplantation 62:376-380, 1996.
28. Fraser VJ, Jones M, Dunkel J, et al: Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 15:414-421, 1992.
29. Lopez-Berestin G, Bodey GP, Frankel LS, et al: Treatment of hepatosplenic candidiasis with liposomal amphotericin B. J Clin Oncol 5:310-317, 1987.
30. Hospenthal DR, Byrd JC, Weiss RB: Successful treatment of invasive aspergillosis complicating prolonged treatment-related neutropenia in acute myelogenous leukemia with amphotericin B lipid complex. Med Pediar Oncol 25:119-122, 1995.
31. Pizzo PA: Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328:1323-1332, 1993.